T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
Hillman Solutions
HLMN
$1.72B
| $111K | ﹤0.01% |
+12,843
| New | +$141K |
|
2727
4D Molecular Therapeutics
FDMT
$603M
| $110K | ﹤0.01% |
15,790
+4,415
| +39% | +$42.9K |
|
2728
1-800-Flowers.com
FLWS
$265M
| $110K | ﹤0.01% |
11,554
+44
| +0.4% | +$486 |
|
2729
Harrow
HROW
$1.45B
| $110K | ﹤0.01% |
15,100
| – | – |
|
2730
NovaGold Resources
NG
$3.41B
| $110K | ﹤0.01% |
22,882
+1,602
| +8% | +$10K |
|
|
AVYA
2731
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
| $110K | ﹤0.01% |
49,082
+10,443
| +27% | +$74.6K |
|
2732
MediciNova
MNOV
$64.5M
| $109K | ﹤0.01% |
43,100
| – | – |
|
2733
IonQ
IONQ
$18.5B
| $108K | ﹤0.01% |
+24,637
| New | +$174K |
|
2734
Root
ROOT
$761M
| $108K | ﹤0.01% |
5,046
-4,432
| -47% | -$120K |
|
|
IVAC
2735
DELISTED
Intevac Inc
IVAC
| $107K | ﹤0.01% |
22,200
| – | – |
|
2736
Frontline
FRO
$9.08B
| $106K | ﹤0.01% |
12,018
+1,178
| +11% | +$10.7K |
|
|
GAN
2737
DELISTED
GAN Ltd
GAN
| $105K | ﹤0.01% |
35,400
-3,455
| -9% | -$12.8K |
|
|
BRY
2738
DELISTED
Berry Corp
BRY
| $104K | ﹤0.01% |
13,649
+1,655
| +14% | +$17.5K |
|
2739
Ocular Therapeutix
OCUL
$2.24B
| $104K | ﹤0.01% |
25,908
+6,167
| +31% | +$23.3K |
|
2740
SFL Corp
SFL
$1.62B
| $104K | ﹤0.01% |
10,961
-113
| -1% | -$1.18K |
|
2741
The ONE Group
STKS
$56.5M
| $103K | ﹤0.01% |
13,959
+2,806
| +25% | +$25.6K |
|
2742
Lufax Holding
LU
$1.31B
| $100K | ﹤0.01% |
4,150
| – | – |
|
2743
Praxis Precision Medicines
PRAX
$10.4B
| $100K | ﹤0.01% |
2,731
+896
| +49% | +$95.6K |
|
|
HIND
2744
Vyome Holdings
HIND
$15.1M
| $99K | ﹤0.01% |
1
| – | – |
|
2745
XBiotech
XBIT
$72.6M
| $99K | ﹤0.01% |
17,600
+3,146
| +22% | +$21.2K |
|
|
SLGCW
2746
DELISTED
SomaLogic, Inc. Warrant
SLGCW
| $99K | ﹤0.01% |
130,769
| – | – |
|
|
TCRR
2747
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $99K | ﹤0.01% |
34,200
-2,581
| -7% | -$6.37K |
|
|
LMACA
2748
DELISTED
Liberty Media Acquisition Corporation Series A Common Stock
LMACA
| $99K | ﹤0.01% |
10,040
| – | – |
|
|
WGSWW
2749
DELISTED
GeneDx Holdings Warrant
WGSWW
| $97K | ﹤0.01% |
297,284
-1
| -0% | – |
|
2750
LSI Industries
LYTS
$906M
| $96K | ﹤0.01% |
15,525
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.